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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the effect of exercise compared to other ACTs for improving respiratory function and other clinical outcomes in people
with CF and to assess the potential adverse effects associated with this method.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a genetic condition inherited in an autoso-
mal recessive fashion (when two mutated genes are inherited, one
from each parent). It is a multisystem disorder predominantly af-
fecting the respiratory, gastrointestinal, endocrine and reproduc-
tive systems. The condition is more prevalent in populations of
Northern European descent (Farrell 2018), with an incidence of
one in every 2381 live births (Farrell 2008).
CF is the result of a mutation in the cystic fibrosis transmembrane
conductance regulator gene (CFTR) which leads to poorly func-
tioning exocrine glands and reduced ion transport across epithe-
lia, resulting in reduced airway surface liquid and a build up of
copious mucus. These viscous secretions cause inflammation and
irreversible damage to the airway epithelia, which in turn leads to
bronchiectasis which then progresses to respiratory failure and is
the reason for CF being life-limiting (Koch 1993).
With recent innovations in immunomodulator therapy and po-
tentiators such as ivacaftor, which demonstrated absolute improve-
ment in forced expiratory volume in one second (FEV1) and de-
creased number of pulmonary exacerbations in people with the
G551D mutation (Skilton 2019), mortality rates have decreased.
The current median survival is 52 years in males and 49 years in
females (Keogh 2018). As the life expectancy of people with CF
continues to rise, disease demographics have changed. Healthcare
teams now face the challenge of maintaining health and optimis-
ing quality of life (QoL). This highlights the important contribu-
tion of exercise and physiotherapy in managing CF.
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Description of the intervention
There is evidence from systematic reviews, including Cochrane
Reviews, that exercise and airway clearance are important formain-
taining respiratory health, even during early stages of the condi-
tion (Flume 2009).
There are many established airway clearance techniques (ACTs)
that have been evaluated in Cochrane Reviews including man-
ual techniques such as postural drainage and percussion (PD&
P) (Main 2005); breathing techniques such as autogenic drainage
(AD) (McCormack 2017) and the active cycle of breathing tech-
nique (ACBT) (Mckoy 2016); oscillating devices (Morrison 2017)
and use of positive expiratory pressure (PEP) devices (McIlwaine
2015). There are other interventions that train respiratory mus-
cles (Hilton 2018; Irons 2016), but since the effects of respiratory
muscle training are above the scope of this review these will not
be comparator interventions in this review. To date, the evidence
surrounding the use of exercise to aid secretion clearance has not
been assessed.
It has been shown that habitual physical activity and exercise
decrease pulmonary exacerbations, hospitalisations and improve
physical function, endurance, energy level and QoL in both chil-
dren and adults with the disease (Boas 1997; Cerny 2013; LeBlanc
2014; Rand 2012; Radtke 2017; Shoemaker 2008; Wheatley
2011). Increasing levels of exercise and physical activity have also
been associated with a slower rate of decline in lung function (Cox
2018; Schneiderman 2014).
Habitual physical activity has been defined as bodily movement
produced regularly by the contraction of skeletal muscles that
results in a substantial increase over resting energy expenditure
(Pescatello 2014). This should be differentiated from exercise
which is planned, structured and repetitive bodily movement per-
formed to improve or maintain one or more components of phys-
ical fitness (Pescatello 2014). Within exercise there are also differ-
ent subgroups including aerobic exercise, anaerobic exercise, resis-
tance, strength, balance and flexibility. For the purpose of this re-
view we will be looking to assess the evidence surrounding all types
of exercise mentioned as a form of airway clearance for people with
CF. This will not be inclusive of respiratory muscle training due
to the similarities and overlap between this and traditional ACT.
How the intervention might work
Exercise is thought to promote clearance of mucus in a multi-
mechanistic way including, mechanical vibration, hyperventila-
tion, coughing and changing the viscosity of sputum (Hebestreit
2001; Radtke 2017; Wilson 2019). This increased mucus clear-
ance leads to the removal of infected secretions within the airways,
reducing the release of inflammatory cytokines which cause direct
effect and damage to the airway epithelia.
In comparison to routine ACTs, exercise has been shown to in-
crease aerobic capacity, the level of activity (Selvadurai 2002) and
potentially train the muscles of respiration (Dassios 2013; Hilton
2018). Aerobic capacity is thought to be one of the best predictors
of survival for people with CF (Gruber 2014). Exercise capacity
and participation in physical training in people with CF have been
related to improved posture, bone density (Hind 2008; Sawyer
2004), mental health, QoL (Klijn 2004) and also to a reduction in
the number of antibiotic days (Urquhart 2012); and so there are
additional benefits to prescribing this form of airway clearance.
Treadmill exercise improvesmucus clearancemechanisms inCFby
increasing peak expiratory flow (PEF) and reducing sputum me-
chanical impedance (Dwyer 2011). Theoretically, varying breath
volumes during exercise and through vigorous activity produces
shearing forces which enhance mucociliary clearance. This facili-
tates the removal of secretions, improves ventilation and reduces
inflammation in the lungs, thus limiting damage to airways.
Why it is important to do this review
OtherCochraneReviews have beenpublisheddemonstratingnon-
superiority between other forms of ACTs such as AD (McCormack
2017), oscillatory devices (Morrison 2017), ACBT (Mckoy 2016),
PEP (McIlwaine 2015) and conventional chest physiotherapy (
Main 2005). As non-superiority exists, there is no globally agreed
definitive treatment strategy for ACTs and their prescription.
Currently, aerobic exercise is recommended for people with CF
as an adjunctive therapy for airway clearance (Flume 2009), but
not prescribed for this purpose alone. A recent Australian survey,
however, showed that 44% of people with CF are using exercise as
a substitute for traditional ACTs, suggesting a potential preference
for this mode of therapy (Ward 2019). In addition, participants
using exercise as a substitute for other ACTs were found to have a
significantly higher FEV1 (% predicted), lower perceived severity
of respiratory disease and lower sputum load than other partici-
pants (Ward 2019).
A key research question identified from people with CF, their care-
givers and clinicians in a priority setting exercise with the James
Lind Alliance (JLA), is whether exercise can be used to replace air-
way clearance in CF (Rowbotham 2018). Adults with CF report
spending an average of 108 minutes on treatment and activities
each day, the majority of that time performing airway clearance
and exercise (Sawicki 2009). It is important thatwe evaluate the ev-
idence in order to help reduce the large treatment burden imposed
on people with CF. It is important to highlight there is a range of
evidence available from different sources. In this review, we will be
summarising the high-quality evidence available from randomised
controlled trials (RCTs) or quasi-RCTs (including cross-over tri-
als) that evaluate ACT and exercise in people with CF.
This review aims to address this gap in the literature. If exercise
does prove to be as effective as other ACTs, it is a safe, easily
accessible and cost-effective strategy to improve the respiratory
health and QoL of people with CF (Williams 2013).
2Exercise versus airway clearance techniques for people with cystic fibrosis (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
O B J E C T I V E S
To compare the effect of exercise compared to other ACTs for im-
proving respiratory function and other clinical outcomes in people
with CF and to assess the potential adverse effects associated with
this method.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs or quasi-RCTs (including cross-over trials) that evaluate
ACTs and exercise in people with CF.
We will exclude trials involving a single intervention (i.e. one ex-
ercise session). Although inhibition of luminal sodium conduc-
tance is thought to increase water content of mucus during exer-
cise in the acute phase (Hebestreit 2001), this review is looking at
the long-term effects of exercise on respiratory health and other
outcomes for people with CF; therefore, trials where therapy is
performed only once, are inappropriate for this review.
Types of participants
We will include children (over four years of age) and adults with
CF with a diagnosis based on sweat testing (sweat chloride over
59 mmol/L), genetic testing or a combination of these. We will
not have any restrictions based on disease severity or exacerbation
status.
Types of interventions
This review will include trials that compare exercise to other recog-
nised ACTs (as described below) either as a single technique or in
combination.
Whilst a single exercise session has been reported to inhibit ep-
ithelial sodium channels and normalize transepithelial potential
difference (Hebestreit 2001), the aim of this review is to estab-
lish whether exercise can replace chest physiotherapy, rather than
explore the mechanism whereby exercise leads to improved mu-
cociliary clearance. Benefits of exercise for airway clearance and
to improve lung function, ventilation and aerobic capacity are
likely to be evident after multiple treatment episodes (Cholewa
2012); therefore, only studies using ACT for at least two treatment
episodes will be included.
Interventions of variable duration will be considered and separated
according to term of intervention (e.g. up to 14 days, 15 days to
12 weeks, over 12 weeks).
Exercise
Exercise is an adjuvant to current methods and is thought to pro-
mote mechanical clearance of mucus through increasing minute
ventilation and PEF (Dwyer 2011). This helps to slow lung func-
tion decline (Schneiderman 2014) and has been associated with
improved survival (Hebestreit 2018; Nixon 1992). Various types
of exercise can be beneficial including cardiovascular, strength and
flexibility training and this review plans to take all types into ac-
count. Trials looking at planned, formal, intensity-specific exercise
will be included. Those that look at physical activity in a more
unstructured way with lower levels of intensity will be considered,
but excluded if they are not completed on a regular basis.
PD&P
PD&P was introduced for managing CF in the 1950s and uses
positioning, manual vibration and gravity to move mucus within
the airways (Main 2005; Wilson 2019).
AD
This is a method of controlled breathing in the expiratory phase
which helps move secretions from the smaller to larger airways
(McCormack 2017). Secretions are cleared by adjusting the speed
and depth of breathing according to where secretions are heard
and felt by the individual. This can be performed independently
without a device or a trained healthcare professional but requires
commitment and training.
ACBT
This is characterised by a combination of relaxation and breathing
control, thoracic expansion exercises with forced expiratory tech-
niques (FET) to achieve mucociliary clearance (Mckoy 2016).
PEP
A PEP device is a mask or mouthpiece used to provide a back pres-
sure to the airways during expiration (McIlwaine 2015). There
is a valve within the device that increases resistance to expiratory
airflow between 10 cm to 20 cm of water (H2O). This stimulates
mucociliary clearance by building up gas behind mucus via collat-
eral ventilation, preventing small airway collapse through stenting
of airways and temporarily increasing functional residual capacity
(FRC) (Groth 1985). Hi-PEP uses full forced expiration against
the PEP mask’s expiratory resistor using pressures of between 40
cm to 140 cm of H2O (Prasad 1993).
Oscillatory devices
There are two main types of oscillatory devices; oscillatory PEP
(O-PEP) devices and those using external thoracic high frequency
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chest wall oscillation (HFCWO). O-PEP devices include, but
are not limited to, the RC-Cornet®, Flutter®, Acapella®, Aer-
obiKA®, Quake® and intrapulmonary percussive ventilation
(IPV). The PEP element of these therapies increases FRC and
augments collateral ventilation (Groth 1985). These devices also
generate intrathoracic oscillation through varying expiratory flow
resistance during exhalation. This combined action helps to mo-
bilize secretions by reducing sputum viscosity and creating small
bursts of air that move secretions centrally and facilitating expec-
toration (McIlwaine 2006). HFCWO uses an inflatable garment
that covers the chest and is attached to an air pulse-generating
compressor, which rapidly inflates and deflates the garment pro-
ducing oscillations tomanipulate the chest wall. It is proposed that
HFCWOenhances mucociliary transport by creating a cough-like
expiratory flow bias that shears mucus from the airway walls by
enhancing ciliary beat frequency (Hansen 1994) and by altering
the rheological properties of mucus (Dasgupta 1998).
Types of outcome measures
Primary outcomes
1. Lung function
i) FEV1 (per cent (%) predicted) absolute change from
baseline values and final value
ii) FEV1 (L) absolute change from baseline values and
final value
2. 2. Exercise capacity
i) peak oxygen uptake (VO2 Peak) in L, mL/kg body
weight or fat-free mass or as % predicted (Hebestreit 2015)
ii) maximal work rate (Wpeak) (Hebestreit 2015)
iii) any validated field test (e.g. six-minute walk test (m),
modified 10-m shuttle test (m))
3. 3. QoL (self-reported)
i) Cystic Fibrosis Questionnaire-Revised (CFQ-R)
(Quittner 2009)
ii) Cystic Fibrosis Quality of Life Questionnaire (CF-
QoL) (Gee 2000)
iii) Chronic Respiratory Disease Questionnaire (CRQ)
(Guyatt 1987)
iv) any other validated QoL scale (e.g. NHP, SF-36)
Secondary outcomes
1. Adverse effects (related to exercise and exercise testing)
2. Lung Function
i) forced vital capacity (FVC) % predicted or litres (L)
ii) mid-forced expiratory flow (FEF25−75)
iii) lung clearance index (LCI)
3. Participant preference
4. Adherence
i) electronic data capture
ii) participant diary
5. Sputum weight
i) wet weight (g)
ii) dry weight (g)
6. Hospital admissions due to exacerbation as defined by
(Rosenfeld 2001)
i) number of hospital admissions
ii) duration of hospital admission
7. Need for extra antibiotics (days)
i) oral
ii) intravenous (IV)
iii) inhaled or nebulised
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
The Cochrane Cystic Fibrosis and Genetic Disorders Group’s In-
formationSpecialist will conduct a systematic search of theGroup’s
Cystic Fibrosis Trials Register for relevant trials using the following
terms: ’exercise’ and ’airway clearance techniques’.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major CF conferences:
the International Cystic Fibrosis Conference; the European Cystic
Fibrosis Conference and theNorth American Cystic Fibrosis Con-
ference. For full details of all searching activities for the register,
please see the relevant section of the Cochrane Cystic Fibrosis and
Genetic Disorders Group’s website.
We will search theWorldHealthOrganization International Clin-
ical Trials Registry Platform (www.who.int/trialsearch) and Clin-
icalTrials.gov ( www.clinicaltrials.gov). The search strategies for
these online databases are presented in the appendices (Appendix
1).
Searching other resources
We will contact experts and organisations in the field to obtain
additional information on relevant trials.
Data collection and analysis
Selection of studies
4Exercise versus airway clearance techniques for people with cystic fibrosis (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Two authors (KP and AW) will independently review all citations
and abstracts retrieved, using the search criteria above to determine
which papers are eligible for inclusion. They will then review the
full text articles. If any conflict arises, they will consult a third
author (PM) to review trials for eligibility.
Data extraction and management
Two authors (KP and AW) will independently extract data using
data extraction forms specifically developed for this purpose. The
extracted data will include the number of participants, participant
characteristics, trial design (type of randomisation, allocation and
concealment), details of the intervention (type of exercise, fre-
quency, duration of session, compliance) and outcome measures.
If data are incomplete, the review authors will contact trial inves-
tigators to collect original data for inclusion.
The authors will use Covidence to manage these data (Covidence)
and will compile and analyse the data using the Cochrane soft-
ware (RevMan 2014). The authors will group the results based
on time (i.e. up to 14 days, 15 days to 12 weeks, over 12 weeks),
but they will not consider single treatment interventions as it is
unlikely that a single treatment will have any long-term effect on
any measured outcome. They plan to present results separately for
each comparison of the different ACTs, e.g. exercise versus PEP,
exercise versus ACBT, etc. They plan to present trials in partic-
ipants hospitalised as inpatients separately to long-term trials in
those who are clinically stable.
Assessment of risk of bias in included studies
Two authors (KP and AW) will independently assess the included
trials for risk of bias using the Cochrane risk of bias tool (Higgins
2011a). This tool is a domain-based evaluation in which critical
assessments are made separately for six different domains (gen-
eration of sequence, concealment of allocation, blinding of par-
ticipants, personnel and outcome assessors, incomplete outcome
data, selective outcome reporting and other potential threats to
validity). They will grade each trial as low risk of bias, unclear risk
of bias or high risk of bias for each domain. A third author (PM),
who is a content expert, will resolve any disagreements.
Measures of treatment effect
For continuous outcomes (FEV1, exercise capacity, QoL, adher-
ence, FVC, FEF25−75 , LCI, sputum weight, duration of hospital
admissions, number of antibiotic days) the authors will report the
mean difference (MD) and 95% confidence intervals (CIs) if tri-
als use the same unit of measurement, otherwise they will use the
standardised mean difference (SMD). In the case of binary out-
comes or dichotomous data (e.g. participant preference, number
of participants admitted to hospital) the authors will combine the
data from the studies using risk ratios (RR) and 95% CIs (Deeks
2011).
Unit of analysis issues
The review authors will consider the level at which the randomi-
sation occurred in the trials (Deeks 2011). They will not include
cluster RCTs, as they do not consider this design appropriate for
exercise as an intervention.
For RCTs with a cross-over design, i.e. where all participants re-
ceive all the interventions and act as their own control, the effects
of one intervention can often persist into the next treatment period
interfering with the effects of the subsequent intervention if there
is not a significant washout period. This is known as the ’carry-
over effect’. When analysing such trials the authors plan to use
the methods suggested by Elbourne (Elbourne 2002). In general,
the reporting of data from cross-over trials is variable with lim-
ited data published that are required for a paired analysis (Higgins
2011b). If the requisite data are not available, the authors plan to
use data from the first arm of the trial and treat it as a parallel trial.
However, this is a conservative approach and the CIs are likely to
be wider, potentially disguising clinically important information
and underestimating the treatment effect (Higgins 2011b).
For trials that have multiple treatment groups, the review authors
will combine all relevant control groups into a single control group
to create a single pair-wise comparison to decrease the unit-of-
analysis error.
Dealing with missing data
In instances of missing data, the review authors will contact the
trial authors directly. Where data remain unavailable, the review
authors will list the trial under ’Studies awaiting classification’ and
will include the trial in future updates, should relevant data become
available.
Assessment of heterogeneity
For trials with similar interventions and participants, assessing
similar outcomes, the review authors will perform a meta-analysis
to pool the data and depicted this in a forest plot. They will assess
heterogeneity using theChi² test (which assesses whether observed
differences in results are compatible with chance alone) and the I²
statistic (which describes the percentage of total variation across
trials due to heterogeneity rather than chance) (Higgins 2003).
The values of I² lie between 0% and 100%. The authors will
categorise heterogeneity according to the Cochrane Handbook for
Systematic Reviews of Interventions as below (Deeks 2011).
• 0% to 40% as little heterogeneity
• 30% to 60% as moderate heterogeneity
• 50% to 90% as substantial heterogeneity
• over 75% as considerable heterogeneity
Using the null hypothesis of homogeneity, the review authors will
deem a P value of 0.1 to be significant.
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Assessment of reporting biases
If the authors identify a sufficient number of trials (i.e. 10 trials)
of different sizes for the review, they plan on creating funnel plots
in RevMan to assess for reporting bias. They will create these by
plotting the standard error of the intervention effect, rather than
the total sample size, on the y-axis (Sterne 2001). Funnel plots are
a visual aid to assess treatment effect against precision. If the trial
is highly precise, the points will lie close to the average, if precision
is lower, the points will lie either side of the average. If asymmetry
or deviation of plot exists, the authors will consider the possibility
of publication bias, as well as selection bias, poor methodological
quality, true heterogeneity and chance (Egger 1997; Sterne 2000;
Sterne 2011).
The review authors will also assess outcome reporting bias. This
is when results for outcomes listed in the methodology are not
published, giving rise tomisleading results (Pocock 1987; Tannock
1996). To reduce this type of bias, for each included trial, the
authors will compare the methods section to the results section
to ensure all variables are reported. The review authors will also
attempt to identify the relevant trial protocols, e.g. from online
trial registries.
Data synthesis
The review authors will analyse data using the fixed-effect
model (Mantel-Haenszel methods) programmed intoRevMan5.3
(Mantel 1959; Greenland 1985). If at least substantial heterogene-
ity (I² value over 50%) exists between identified trials, they will
use the random-effects model for analysis (Deeks 2011).
Subgroup analysis and investigation of heterogeneity
If the review includes sufficient data, they will investigate hetero-
geneity by performing a separate subgroup analysis based on the
participant characteristics:
1. age (four years to 17 years compared with adults);
2. gender;
3. disease severity based on lung function (FEV1 % predicted,
over 90%, 50% to 89%, below 50%).
Sensitivity analysis
If the review authors are able to combine the data from multiple
trials, they will test the robustness of the results by performing
a sensitivity analysis, presented in the form of a summary table.
They will analyse the effect of trial design (parallel versus cross-
over), allocation concealment (high risk of bias versus low risk of
bias) and loss to follow-up (high risk of bias versus low risk of bias)
on the results.
Summary of findings tables
The review authors will determine and rate the quality of evidence
for each outcome by using the GRADE approach (Schünemann
2011a; Schünemann 2011b). This will be presented in the sum-
mary of findings (SoF) tables (one for each comparison). The out-
comes selected for individual comparison are those that the au-
thors feel are patient-important outcomes.
• Pulmonary function - absolute change FEV1 % predicted
• Exercise capacity - change in VO2 peak during maximal
exercise (mL/min per kg body weight)
• QoL - CFQ-R
• Adverse effects
• Participant preference
• Adherence
• Need for any extra antibiotics (oral, IV, inhaled or
nebulised) in days
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A P P E N D I C E S
Appendix 1. Electronic search strategies
ClinicalTrials.gov
(www.clinicaltrials.gov/)
RECRUITMENT STATUS: All studies
CONDITION OR DISEASE: cystic fibrosis
OTHER TERMS: Exercise AND (airway clearance OR oscillating devices
OR postural drainage OR percussion OR active cycle OR positive expira-
tory pressure OR autogenic drainage)
WHO ICTRP
(apps.who.int/trialsearch/Default.aspx)
Advanced search
Recruitment status: ALL
Search 1:
Condition: cystic fibrosis
AND
Intervention: exercise AND airway clearance
Search 2:
Condition: cystic fibrosis
AND
Intervention: exercise AND oscillating devices
Search 3:
Condition: cystic fibrosis
AND
Intervention: exercise AND postural drainage
Search 4 :
Condition: cystic fibrosis
AND
Intervention: exercise AND percussion
Search 5 :
Condition: cystic fibrosis
AND
Intervention: exercise AND active cycle
Search 6:
Condition: cystic fibrosis
AND
Intervention: exercise AND positive expiratory pressure
Search 7:
Condition: cystic fibrosis
AND
Intervention: exercise AND autogenic drainage
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C O N T R I B U T I O N S O F A U T H O R S
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TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol KP
Review stage: select which trials to include (2 + 1 arbiter) KP and AW (PMC)
Review stage: extract data from trials (2 people) KP and AW
Review stage: enter data into RevMan KP
Review stage: carry out the analysis KP, AW, PMC and KS
Review stage: interpret the analysis KP, AW, PMC and KS
Review stage: draft the final review KP
Update stage: update the review KP, AW, PMC and KS
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